MGTA · Magenta Therapeutics
Acquired Company
Magenta Therapeutics completed its merger with Dianthus Therapeutics on 9/11/2023, and the combined company began trading as Dianthus Therapeutics, Inc. under the ticker DNTH on 9/12/2023.
Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$0.76
Open
$0.71
Volume
376,060
Day Range
$0.68 - $0.76
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
2.23%
Institutional Own.
62.64%
Qtr Updated
Mar 31st 2024